Sino Biopharmaceutical (OTCMKTS:SBMFF) Hits New 1-Year Low at $0.44

Sino Biopharmaceutical Limited (OTCMKTS:SBMFFGet Rating)’s share price reached a new 52-week low on Wednesday . The company traded as low as $0.44 and last traded at $0.44, with a volume of 10850 shares. The stock had previously closed at $0.48.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft began coverage on Sino Biopharmaceutical in a report on Tuesday, August 2nd. They set a “buy” rating for the company.

Sino Biopharmaceutical Stock Performance

The business has a fifty day simple moving average of $0.54 and a two-hundred day simple moving average of $0.54.

About Sino Biopharmaceutical

(Get Rating)

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections.

Featured Articles

Receive News & Ratings for Sino Biopharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.